Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
复制标题
DOI：
10.1111/cas.12319
复制
发表时间：
2014-01
期刊：
影响因子：
5.7
通讯作者：
Japan Adult Leukemia Study Group
中科院分区：
文献类型：
--
作者：
Ono T;Takeshita A;Kishimoto Y;Kiyoi H;Okada M;Yamauchi T;Emi N;Horikawa K;Matsuda M;Shinagawa K;Monma F;Ohtake S;Nakaseko C;Takahashi M;Kimura Y;Iwanaga M;Asou N;Naoe T;Japan Adult Leukemia Study Group
CD 56的表达最近被认为是急性早幼粒细胞白血病（APL）的不良预后因素之一。然而，CD 56抗原在APL中的临床意义尚未得到很好的阐明。我们根据日本成人白血病研究组APL 97方案，评估了239例APL患者中CD 56抗原的临床意义，这些患者前瞻性地接受了全反式维甲酸和化疗。所有患者均按照日本成人白血病研究组APL 97方案进行前瞻性治疗。中位随访期为8.5年。APL患者中23例（9.6%）CD 56阳性表达。CD 56的表达与血小板计数降低（P = 0.04）、严重弥散性血管内凝血（P = 0.04）以及CD 2（P = 0.03）、CD 7（P = 0.04）、CD 34（P < 0.01）和/或人类白细胞抗原DR（P < 0.01）的共同表达显着相关。两组的完全缓解率和总生存率无差异。然而，累积复发率和无事件生存期（EFS）显示CD 56 + APL的劣化趋势（分别为P = 0.08和P = 0.08）。在初始白色血细胞计数≥ 3.0 × 109/L的患者中，CD 56 + APL患者的EFS和累积复发率显著更差（分别为30.8% vs 63.6%，P = 0.008和53.8% vs 28.9%，P = 0.03），在多变量分析中，CD 56表达是EFS的不利预后因素（P = 0.04）。总之，对于具有较高初始白色血细胞计数的APL，CD 56表达应被视为不利的预后因素。
Expression of CD56 has recently been introduced as one of the adverse prognostic factors in acute promyelocytic leukemia (APL). However, the clinical significance of CD56 antigen in APL has not been well elucidated. We assessed the clinical significance of CD56 antigen in 239 APL patients prospectively treated with all-trans retinoic acid and chemotherapy according to the Japan Adult Leukemia Study Group APL97 protocol. All patients were prospectively treated by the Japan Adult Leukemia Study Group APL97 protocol. The median follow-up period was 8.5 years. Positive CD56 expression was found in 23 APL patients (9.6%). Expression of CD56 was significantly associated with lower platelet count (P = 0.04), severe disseminated intravascular coagulation (P = 0.04), and coexpression of CD2 (P = 0.03), CD7 (P = 0.04), CD34 (P < 0.01) and/or human leukocyte antigen-DR (P < 0.01). Complete remission rate and overall survival were not different between the two groups. However, cumulative incidence of relapse and event-free survival (EFS) showed an inferior trend in CD56+ APL (P = 0.08 and P = 0.08, respectively). Among patients with initial white blood cell counts of 3.0 × 109/L or more, EFS and cumulative incidence of relapse in CD56+ APL were significantly worse (30.8% vs 63.6%, P = 0.008, and 53.8% vs 28.9%, P = 0.03, respectively), and in multivariate analysis, CD56 expression was an unfavorable prognostic factor for EFS (P = 0.04). In conclusion, for APL with higher initial white blood cell counts, CD56 expression should be regarded as an unfavorable prognostic factor.
登录
查看更多内容
影响因子：
20.3
作者：
Estey, E;Garcia-Manero, G;Kantarjian, H
通讯作者：
Kantarjian, H
影响因子：
45.3
作者：
Ravandi, Farhad;Estey, Eli;Kantarjian, Hagop
通讯作者：
Kantarjian, Hagop
影响因子：
20.3
作者：
Lo-Coco, Francesco;Avvisati, Giuseppe;Mandelli, Franco
通讯作者：
Mandelli, Franco
影响因子：
20.3
作者：
Purton, LE;Bernstein, ID;Collins, SJ
通讯作者：
Collins, SJ
影响因子：
11.4
作者：
Raspadori, D;Damiani, D;Lauria, F
通讯作者：
Lauria, F